HCK and pancreatic ductal adenocarcinoma: Previous studies have determined that inhibition of HCK can target TAMs, which leads to the reduction of infiltrated immune cells, lessened immunosuppression, and an improved efficacy for chemotherapy pancreatic ductal adenocarcinoma [31].